Table 2.

Demographic and clinical characteristics of patients enrolled in the performance improvement program (n = 408), November 2015–February 2017

Preventive therapy
Yes (n = 222)No (n = 186)
Total n = 408n (%)n (%)P
Type of lesion
 Lobular carcinoma in situ6840 (58.8)28 (41.2)
 Atypical hyperplasia340182 (53.5)158 (46.5)0.50
Age
 ≤4098 (88.8)1 (11.2)
 41–508144 (54.3)37 (45.7)
 51–6017596 (54.8)79 (45.2)
 ≥6114374 (51.7)69 (48.3)0.19
Race/ethnicity
 White291161 (55.3)130 (44.7)
 Black3517 (48.6)18 (51.4)
 Hispanic4527 (60.0)18 (40.0)
 Asian3015 (50.0)15 (50.0)
 Other72 (28.6)5 (71.4)0.53
Diagnosis status
 New8771 (81.6)16 (18.4)
 Existing321151 (47.0)170 (53.0)<0.01
Time from diagnosis to enrollment (years)a
 Median 6.2 (range, 0.6–33.2)
 ≤38749 (56.3)38 (43.7)
 >3–914261 (42.9)81 (57.1)
 >9–156632 (48.5)34 (51.5)
 >15247 (12.2)17 (70.8)0.07
Ptrend = 0.04
  • aAmong patients with an existing diagnosis of atypical hyperplasia/lobular cancer in situ.